Eterna Therapeutics closes $1.1M private placement, exchanges debt for equity, addresses Nasdaq compliance

Ernexa Therapeutics Inc.

Stockholders approved issuance of shares for September 2024 transactions at Oct 29 annual meeting.
Closed private placement: issued 1,401,994 shares + 115,000 pre-funded warrants; gross proceeds $1.1M.
Exchange transactions: issued 38,302,029 shares for outstanding warrants and convertible notes.
Bridge notes converted: 6,244,237 shares + 1,764,000 pre-funded warrants; $0.50 conversion price.
Post-closing cap: ~51.4M shares outstanding; Nasdaq hearing on Nov 12 to address equity compliance.

item 1.01 item 8.01 item 3.02 item 5.07 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.